CN111388466A - Pharmaceutical composition containing andrographolide and preparation thereof - Google Patents
Pharmaceutical composition containing andrographolide and preparation thereof Download PDFInfo
- Publication number
- CN111388466A CN111388466A CN201811652632.0A CN201811652632A CN111388466A CN 111388466 A CN111388466 A CN 111388466A CN 201811652632 A CN201811652632 A CN 201811652632A CN 111388466 A CN111388466 A CN 111388466A
- Authority
- CN
- China
- Prior art keywords
- andrographolide
- pharmaceutical composition
- cyclodextrin
- surfactant
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- BOJKULTULYSRAS-OTESTREVSA-N Andrographolide Chemical compound C([C@H]1[C@]2(C)CC[C@@H](O)[C@]([C@H]2CCC1=C)(CO)C)\C=C1/[C@H](O)COC1=O BOJKULTULYSRAS-OTESTREVSA-N 0.000 title claims abstract description 161
- ASLUCFFROXVMFL-UHFFFAOYSA-N andrographolide Natural products CC1(CO)C(O)CCC2(C)C(CC=C3/C(O)OCC3=O)C(=C)CCC12 ASLUCFFROXVMFL-UHFFFAOYSA-N 0.000 title claims abstract description 160
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 72
- 238000002360 preparation method Methods 0.000 title abstract description 20
- 229920000858 Cyclodextrin Polymers 0.000 claims abstract description 69
- 239000004094 surface-active agent Substances 0.000 claims abstract description 31
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims abstract description 24
- 239000000243 solution Substances 0.000 claims description 26
- 239000002202 Polyethylene glycol Substances 0.000 claims description 22
- 229940080345 gamma-cyclodextrin Drugs 0.000 claims description 22
- 229920001223 polyethylene glycol Polymers 0.000 claims description 22
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims description 20
- GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 claims description 19
- 239000011782 vitamin Substances 0.000 claims description 19
- 229940088594 vitamin Drugs 0.000 claims description 19
- 239000006187 pill Substances 0.000 claims description 16
- 229930003231 vitamin Natural products 0.000 claims description 15
- 235000013343 vitamin Nutrition 0.000 claims description 15
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 15
- 239000001116 FEMA 4028 Substances 0.000 claims description 9
- 235000011175 beta-cyclodextrine Nutrition 0.000 claims description 9
- 229960004853 betadex Drugs 0.000 claims description 9
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 6
- 229960000502 poloxamer Drugs 0.000 claims description 6
- 229920001983 poloxamer Polymers 0.000 claims description 6
- 239000003826 tablet Substances 0.000 claims description 6
- YZOUYRAONFXZSI-SBHWVFSVSA-N (1S,3R,5R,6R,8R,10R,11R,13R,15R,16R,18R,20R,21R,23R,25R,26R,28R,30R,31S,33R,35R,36R,37S,38R,39S,40R,41S,42R,43S,44R,45S,46R,47S,48R,49S)-5,10,15,20,25,30,35-heptakis(hydroxymethyl)-37,39,40,41,42,43,44,45,46,47,48,49-dodecamethoxy-2,4,7,9,12,14,17,19,22,24,27,29,32,34-tetradecaoxaoctacyclo[31.2.2.23,6.28,11.213,16.218,21.223,26.228,31]nonatetracontane-36,38-diol Chemical compound O([C@@H]([C@H]([C@@H]1OC)OC)O[C@H]2[C@@H](O)[C@@H]([C@@H](O[C@@H]3[C@@H](CO)O[C@@H]([C@H]([C@@H]3O)OC)O[C@@H]3[C@@H](CO)O[C@@H]([C@H]([C@@H]3OC)OC)O[C@@H]3[C@@H](CO)O[C@@H]([C@H]([C@@H]3OC)OC)O[C@@H]3[C@@H](CO)O[C@@H]([C@H]([C@@H]3OC)OC)O3)O[C@@H]2CO)OC)[C@H](CO)[C@H]1O[C@@H]1[C@@H](OC)[C@H](OC)[C@H]3[C@@H](CO)O1 YZOUYRAONFXZSI-SBHWVFSVSA-N 0.000 claims description 5
- 239000000725 suspension Substances 0.000 claims description 5
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 claims description 5
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 4
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims description 4
- 239000004359 castor oil Substances 0.000 claims description 4
- 235000019438 castor oil Nutrition 0.000 claims description 4
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 4
- 239000008187 granular material Substances 0.000 claims description 4
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 4
- 229920000053 polysorbate 80 Polymers 0.000 claims description 4
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 4
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 claims description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 3
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 claims description 3
- 229940043377 alpha-cyclodextrin Drugs 0.000 claims description 3
- -1 polyoxyethylene Polymers 0.000 claims description 3
- 229920001214 Polysorbate 60 Polymers 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 claims description 2
- GGHPAKFFUZUEKL-UHFFFAOYSA-M sodium;hexadecyl sulfate Chemical compound [Na+].CCCCCCCCCCCCCCCCOS([O-])(=O)=O GGHPAKFFUZUEKL-UHFFFAOYSA-M 0.000 claims description 2
- 239000006188 syrup Substances 0.000 claims description 2
- 235000020357 syrup Nutrition 0.000 claims description 2
- 239000008188 pellet Substances 0.000 claims 1
- 229940080236 sodium cetyl sulfate Drugs 0.000 claims 1
- 238000012360 testing method Methods 0.000 abstract description 9
- 230000000694 effects Effects 0.000 abstract description 8
- 238000000338 in vitro Methods 0.000 abstract description 8
- 238000001727 in vivo Methods 0.000 abstract description 7
- 238000012512 characterization method Methods 0.000 abstract description 3
- 210000004027 cell Anatomy 0.000 description 32
- 238000000034 method Methods 0.000 description 24
- 239000000203 mixture Substances 0.000 description 22
- 238000002474 experimental method Methods 0.000 description 19
- 239000003814 drug Substances 0.000 description 16
- 229940079593 drug Drugs 0.000 description 15
- 238000009472 formulation Methods 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 239000002904 solvent Substances 0.000 description 11
- 150000001875 compounds Chemical class 0.000 description 10
- 102100033350 ATP-dependent translocase ABCB1 Human genes 0.000 description 8
- 238000001514 detection method Methods 0.000 description 8
- 108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 7
- 241000700159 Rattus Species 0.000 description 7
- 238000004090 dissolution Methods 0.000 description 7
- 239000011259 mixed solution Substances 0.000 description 7
- 239000012981 Hank's balanced salt solution Substances 0.000 description 6
- 239000007853 buffer solution Substances 0.000 description 6
- 238000004128 high performance liquid chromatography Methods 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 238000000329 molecular dynamics simulation Methods 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 238000005303 weighing Methods 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 229940097362 cyclodextrins Drugs 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000007901 soft capsule Substances 0.000 description 3
- 239000007779 soft material Substances 0.000 description 3
- 238000001291 vacuum drying Methods 0.000 description 3
- 206010067484 Adverse reaction Diseases 0.000 description 2
- 238000001157 Fourier transform infrared spectrum Methods 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 235000019658 bitter taste Nutrition 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 230000004700 cellular uptake Effects 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 238000000113 differential scanning calorimetry Methods 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000010812 external standard method Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 239000012982 microporous membrane Substances 0.000 description 2
- 239000004005 microsphere Substances 0.000 description 2
- 239000004570 mortar (masonry) Substances 0.000 description 2
- 239000006069 physical mixture Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000003825 pressing Methods 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 238000002390 rotary evaporation Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 230000032895 transmembrane transport Effects 0.000 description 2
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 241000207965 Acanthaceae Species 0.000 description 1
- 208000009304 Acute Kidney Injury Diseases 0.000 description 1
- 206010002199 Anaphylactic shock Diseases 0.000 description 1
- 241000746375 Andrographis Species 0.000 description 1
- 244000118350 Andrographis paniculata Species 0.000 description 1
- 208000004429 Bacillary Dysentery Diseases 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- 206010017915 Gastroenteritis shigella Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000005647 Mumps Diseases 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000033626 Renal failure acute Diseases 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- ZAKOWWREFLAJOT-ADUHFSDSSA-N [2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-3,4-dihydrochromen-6-yl] acetate Chemical group CC(=O)OC1=C(C)C(C)=C2OC(CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-ADUHFSDSSA-N 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 208000012873 acute gastroenteritis Diseases 0.000 description 1
- 201000011040 acute kidney failure Diseases 0.000 description 1
- 208000012998 acute renal failure Diseases 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000036436 anti-hiv Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000003353 bioavailability assay Methods 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000011258 core-shell material Substances 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 125000004855 decalinyl group Chemical group C1(CCCC2CCCCC12)* 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000007922 dissolution test Methods 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 229960003943 hypromellose Drugs 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 150000002596 lactones Chemical group 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000011812 mixed powder Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 208000010805 mumps infectious disease Diseases 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 235000011837 pasties Nutrition 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229940057838 polyethylene glycol 4000 Drugs 0.000 description 1
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 208000020029 respiratory tract infectious disease Diseases 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 201000005113 shigellosis Diseases 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 239000007962 solid dispersion Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
- 206010044008 tonsillitis Diseases 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Gastroenterology & Hepatology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Urology & Nephrology (AREA)
- Otolaryngology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses a pharmaceutical composition containing andrographolide, a preparation method and a preparation thereof. The pharmaceutical composition comprises a) andrographolide, b) cyclodextrin and c) surfactant, wherein the molar ratio of andrographolide to cyclodextrin is 1: 2-1: 5, and the mass percent of the surfactant is 0.1% -5%. The andrographolide-containing pharmaceutical composition has high ternary system solubility, and in-vitro characterization tests, cell tests and pharmacokinetic tests show that the pharmaceutical composition improves the in-vivo bioavailability of andrographolide, so that the clinical curative effect can be improved.
Description
Technical Field
The invention relates to the technical field of medicines, and particularly relates to a pharmaceutical composition containing andrographolide and a preparation thereof.
Background
Andrographolide is the main effective component of andrographis paniculata of acanthaceae, has poor solubility in water, is generally called as bitter king, and has the effects of relieving fever, resisting inflammation, resisting virus, resisting platelet aggregation, protecting liver and benefiting gallbladder. Experiments show that the andrographolide has the effects of inhibiting and delaying the body temperature rise caused by the pneumococci or hemolytic streptococcus B, and has a certain anti-HIV effect. Andrographolide is mainly used for clinically treating bacillary dysentery, acute gastroenteritis, epidemic parotitis, tonsillitis, pharyngolaryngitis, upper respiratory infection, urinary infection and the like, and is widely applied as a traditional Chinese medicine antibiotic at present. The dosage forms recorded in the Chinese pharmacopoeia of 2015 edition include andrographolide dripping pills, andrographis tablets and andrographolide capsules. Andrographolide is also marketed in the form of injection, but in recent years, adverse reactions are reported to increase day by day, and rash, dizziness, gastrointestinal reactions, severe anaphylactic shock, acute renal failure and the like can occur frequently.
P-glycoprotein (P-gp) is widely distributed in the endothelial cells of the capillaries of liver, adrenal gland, intestinal mucosa, brain and testis, and has the function of reverse transport of drugs. Besides that andrographolide has low solubility in water and is easy to hydrolyze under weak alkaline conditions, andrographolide is easy to be discharged by P-glycoprotein and is subjected to first-pass metabolism, which is also an important reason for low bioavailability, and the production and application of andrographolide are greatly limited by the factors.
In recent years, there have been increasing reports of andrographolide, and many techniques have been applied to solve the problem of low bioavailability. Patent publication No. CN1568970A describes an andrographolide drop pill and its preparation method. The main technology is that the andrographolide crystal and polyethylene glycol mixture are prepared into solid dispersion with the mass ratio of 1:3, wherein the polyethylene glycol mixture is prepared by mixing polyethylene glycol 4000 and polyethylene glycol 6000 with the mass ratio of 1: 1. In addition, a film coating is also carried out in the process of preparing the andrographolide dropping pills to cover the bitter taste of the andrographolide. The formula is applied to the products on the market, but the solubility and dissolution test results are not seen.
Patent publication No. CN104557818A describes a method for extracting andrographolide, and herba Andrographitis extract containing andrographolide compounds and medicinal adjuvants are prepared into herba Andrographitis dripping pill and herba Andrographitis soft capsule. In order to improve the purity of andrographolide, a new crystal form of andrographolide is prepared and the drug effect of andrographolide is verified. This patent focuses on the extraction and preparation of a new form of andrographolide, and does not elucidate the results of improving its solubility and bioavailability.
Patent publication No. CN108042512A discloses an andrographolide-loaded core-shell alginate/polyacrylamide microsphere, and a preparation method and application thereof. The andrographolide polymer microspheres prepared by the invention can be used for loading a large amount of andrographolide, and have the advantages of high encapsulation rate, controllable size, capability of masking bitter taste, increase of clinical application range and the like. However, the invention does not carry out in vivo and in vitro bioavailability research experiments and does not show that the bioavailability of the compound is obviously improved.
The invention discloses a soft capsule preparation of andrographolide and its preparing method, which comprises preparing clathrate from andrographolide and β -cyclodextrin at a ratio of 1:3, and preparing soft capsule by pressing method, wherein the product can fully cover the bad smell of andrographolide and improve its bioavailability, and has little adverse reaction.
In order to solve the problem of low bioavailability of andrographolide, researches in these years mainly focus on solving the problems that andrographolide is low in water solubility and andrographolide is easy to hydrolyze under a weak alkaline condition, and no one has studied about solving the problems that andrographolide is easy to be discharged by P glycoprotein and metabolized in the first pass.
Disclosure of Invention
The invention aims to provide a pharmaceutical composition containing andrographolide, which has good solubility and high bioavailability.
The second purpose of the invention is to provide an andrographolide preparation, which comprises a pharmaceutical composition of andrographolide with good solubility and high bioavailability.
In order to achieve the above object, the present invention provides the following technical solutions.
One aspect of the present invention provides a pharmaceutical composition containing andrographolide, comprising: a) andrographolide, b) cyclodextrin and c) surfactant, wherein the molar ratio of andrographolide to cyclodextrin is 1: 2-1: 5, and the mass percent of the surfactant is 0.1% -5%.
Furthermore, the pharmaceutical composition containing andrographolide, disclosed by the invention, has the molar ratio of andrographolide to cyclodextrin of 1: 2-1: 3, and the surfactant accounts for 0.1% -1% of the pharmaceutical composition.
Furthermore, the pharmaceutical composition containing andrographolide, provided by the invention, is characterized in that the cyclodextrin is one or more selected from α -cyclodextrin, β -cyclodextrin, gamma-cyclodextrin, hydroxypropyl- β -cyclodextrin, methyl- β -cyclodextrin or sulfobutyl- β -cyclodextrin.
Furthermore, the pharmaceutical composition containing andrographolide, provided by the invention, is characterized in that the surfactant is one or more selected from sodium dodecyl sulfate, sodium hexadecyl sulfate, tween 60, tween 80, benzyl S10, benzyl S20, vitamin E-polyethylene glycol succinate, poloxamer P188, poloxamer P407 and polyoxyethylene castor oil E L.
Furthermore, in the pharmaceutical composition containing andrographolide, the cyclodextrin is gamma-cyclodextrin.
Furthermore, in the andrographolide-containing pharmaceutical composition, the surfactant is one or more of tween 80, vitamin E-polyethylene glycol succinate, poloxamer P407 and polyoxyethylene castor oil E L.
Furthermore, in the pharmaceutical composition containing andrographolide, the surfactant is vitamin E-polyethylene glycol succinate.
Furthermore, the mole ratio of the andrographolide to the cyclodextrin in the pharmaceutical composition containing andrographolide is 1: 2.
Furthermore, in the pharmaceutical composition containing andrographolide, the surfactant accounts for 1% of the pharmaceutical composition by mass.
In another aspect of the present invention, there is provided a method for preparing the ternary system pharmaceutical composition containing andrographolide, comprising the steps of: adding solvent into andrographolide, cyclodextrin and surfactant, mixing the above components, reacting, and removing solvent to obtain dry medicinal composition.
Further, the solvent comprises: one or more of water, methanol, ethanol, acetone and dichloromethane.
Further, the method for removing the solvent comprises one or more of a drying method, a vacuum drying method, a freeze drying method, a spray drying method and a rotary evaporation method.
Further, the preparation method of the ternary system pharmaceutical composition containing andrographolide comprises the following steps:
a) dissolving a surfactant in a solvent, and stirring the solution into a uniform mixed solution by using ultrasonic or magnetic force;
b) adding cyclodextrin into solution containing surfactant, dissolving, adding andrographolide into the mixed solution, and mixing the above components to obtain andrographolide mixed solution;
c) removing the solvent to obtain a dried finished product.
Furthermore, the method for removing the solvent is a drying method, and the andrographolide mixed solution is dried at 50 ℃ to obtain a final finished product;
furthermore, the method for removing the solvent is a vacuum drying method, and the andrographolide mixed solution is placed in a vacuum drying oven for drying to obtain a final finished product;
furthermore, the method for removing the solvent is a freeze-drying method, and the andrographolide mixed solution is subjected to freeze-drying to obtain a final finished product;
furthermore, the method for removing the solvent is a rotary evaporation method, and the mixed solution of andrographolide is volatilized at 65 ℃ to remove the solvent, so as to obtain the final product.
In another aspect of the present invention, a pharmaceutical preparation is provided, which comprises the aforementioned pharmaceutical composition containing andrographolide and a pharmaceutically acceptable carrier.
Further, the formulation may be any one of tablets, capsules, dripping pills, granules, concentrated pills, suspensions, solutions, emulsions, syrups and elixirs.
Further, pharmaceutically acceptable carriers in the preparation include various diluents, excipients, fillers, emulsifiers, binders, lubricants, disintegrants, antioxidants, and the like, which are conventional in the pharmaceutical field.
On the basis of the common knowledge in the field, the above preferred conditions can be combined randomly to obtain the preferred embodiments of the invention.
The reasons for the low bioavailability of andrographolide include the following: firstly, andrographolide has low solubility in water, secondly andrographolide is easy to hydrolyze under the alkalescent condition, thirdly, andrographolide is easy to be discharged by P glycoprotein at the tail end of the intestine and to be metabolized in the first pass, etc.
One of the common methods of increasing the solubility of compounds is to form a molecular composite from a poorly soluble compound with a carrier molecular cavity to increase solubility. The invention adopts the addition of cyclodextrin to achieve the purpose of improving the solubility of andrographolide, and surfactant is added on the basis to form a ternary system pharmaceutical composition. The surfactants of the invention have the effect of inhibiting the efflux of P-glycoprotein, and after the surfactants are added, the efflux rate of andrographolide by P-glycoprotein is obviously reduced, thereby improving the bioavailability of andrographolide. In vitro characterization tests, cell tests and pharmacokinetic tests in the examples all show that the ternary system pharmaceutical composition provided by the invention effectively improves in vivo and in vitro bioavailability of andrographolide, and can improve clinical treatment effects.
Drawings
FIG. 1 phase solubility curves for the andrographolide-cyclodextrin system of example 1.
Figure 2 is a graph of the solubility of the andrographolide-cyclodextrin system of example 2.
FIG. 3 is a schematic diagram of the molecular dynamics simulation of the andrographolide-cyclodextrin system of example 3.
Figure 4. results of MDCK-MDR1 cytotoxicity of andrographolide- γ -cyclodextrin-surfactant ternary system in example 4.
FIG. 5 shows the result of cellular uptake of MDCK-MDR1 in the ternary system of andrographolide-gamma-cyclodextrin-surfactant of example 5.
FIG. 6 shows the results of the MDCK-MDR1 cell transmembrane transport experiment in the ternary system of andrographolide-gamma-cyclodextrin-surfactant in example 6.
Figure 7 is a solubility chart of the highly soluble andrographolide formulation of example 7.
Figure 8 is a graph of the percentage in vitro cumulative release versus time for the highly soluble andrographolide formulation of example 7.
Figure 9 is a DSC of the highly soluble andrographolide formulation of the present invention from example 7.
FIG. 10 is a Fourier transform infrared spectrum of the highly soluble andrographolide formulation of example 7.
FIG. 11 is the plasma concentration-time curve of rats prescribed with andrographolide of the present invention having high solubility in example 7.
Detailed Description
The inventor of the invention creatively discovers the andrographolide-cyclodextrin-surfactant ternary system pharmaceutical composition through a large amount of experimental researches aiming at the defects of the prior art. Compared with andrographolide bulk drugs, the solubility of the ternary pharmaceutical composition is greatly improved, and the dissolution rate and the cumulative dissolution rate of andrographolide are remarkably improved. In addition, MDCK-MDR1 cell model tests show that the pharmaceutical composition containing andrographolide can improve the absorption of andrographolide in MDCK-MDR1 cell models and remarkably reduce the efflux of P glycoprotein, so that the bioavailability of rats in vivo is improved.
Example 1 Cyclodextrin species investigation
A phase solubility curve was prepared by preparing solutions of different types of cyclodextrin (α -cyclodextrin, β -cyclodextrin, γ -cyclodextrin, hydroxypropyl- β -cyclodextrin, methyl- β -cyclodextrin and sulfobutyl- β -cyclodextrin) at concentrations of 0mM, 1.5mM, 3mM, 6mM, 9mM, 12mM, 15mM, each 1m L, adding andrographolide 5mg, respectively, and performing a phase solubility test, and after sufficient dissolution, determining the concentration of andrographolide dissolved in the solution, using the molar concentration of cyclodextrin as abscissa and the aqueous solubility of andrographolide as ordinate.
The detection method comprises detecting with high performance liquid chromatography under the conditions of Eclipse XDB C18 column (250mm × 4.6.6 mm, 5 μm), protective column Eclipse XDB C18 column (12.5mm × 4.6.6 mm, 5 μm), mobile phase methanol-water (1: 1), column temperature of 30 deg.C, detection wavelength of 225nm, and flow rate of 1.0m L min-1The sample injection amount is 10u L. the detection result is shown in figure 1.
The experimental result shows that the andrographolide has better solubility in gamma-cyclodextrin, methyl- β -cyclodextrin and hydroxypropyl- β -cyclodextrin sulfobutyl- β -cyclodextrin, and has the best solubility in the gamma-cyclodextrin.
Example 2 Andrographolide to Cyclodextrin molar ratio examination
Preparing andrographolide-cyclodextrin inclusion compounds with molar concentrations of 1: 1 and 1:2, wherein the detailed formula and formulation are shown in table 1. precisely weighing 25mg of each inclusion compound, respectively adding into 5m L of water, and measuring the concentration of andrographolide dissolved in the solution after the inclusion compound is fully dissolved.
Table 1 recipe ingredients table
The detection method comprises detecting with high performance liquid chromatography under the conditions of Eclipse XDB C18 column (250mm × 4.6.6 mm, 5 μm), protective column Eclipse XDB C18 column (12.5mm × 4.6.6 mm, 5 μm), mobile phase methanol-water (1: 1), column temperature of 30 deg.C, detection wavelength of 225nm, and flow rate of 1.0m L. min-1The sample injection amount is 10u L. the detection result is shown in FIG. 2.
The experimental result shows that the molar ratio of andrographolide to cyclodextrin is 1: the effect is better at 2 days.
Example 3 simulation experiment of molecular dynamics of andrographolide-cyclodextrin system
The invention provides a molecular dynamics simulation method for interaction between andrographolide and gamma-cyclodextrin, hydroxypropyl- β -cyclodextrin, methyl- β -cyclodextrin and sulfobutyl- β -cyclodextrin, which intuitively presents the state and interaction of molecules between andrographolide and various cyclodextrins.
Firstly, using Discovery Studio 2016 to construct molecular structures of andrographolide and different cyclodextrins, and then constructing two different insertion forms of andrographolide according to AutoDock Tools and AutoDock Vina as initial structures of molecular dynamics simulation. Placing different initial structures in the container respectively
In the water box of (1), heating to 310K after energy minimizationA molecular dynamics simulation experiment of 50ns resulted in the most stable structure of andrographolide-cyclodextrin inclusion compound, and the results are shown in FIG. 3.
The experimental results show that the inclusion compound formed by inserting the lactone ring into the cavity of the gamma-cyclodextrin is the most stable when the andrographolide and the gamma-cyclodextrin form the inclusion compound, and the inclusion compound formed by inserting the decalin ring into the cavity of the cyclodextrin is the most stable in other cyclodextrins.
EXAMPLE 4 MDCK-MDR1 cytotoxicity assay of Andrographolide-gamma-cyclodextrin-surfactant ternary System
The operation method comprises the step of inoculating the MDCK-MDR1 cells into a 96-well plate in a suspension manner, wherein the inoculation density is 1 × 104Per well, outermost round 100. mu. L PBS was added to prevent edge effects placing cells in 5% CO2After 24 hours of culture in an incubator at 37 ℃, old culture solution is aspirated, 100 mu L (see table 2) of fresh culture solution with the prescribed concentration is added, the cells after adding the drugs are put back into the incubator for 3 hours, the old culture solution is aspirated, 100 mu L of fresh culture solution (containing 10 mu L of thiazole blue and no serum) is added, the cells are taken out after 2 hours of incubation, 100 mu L DMSO is added after the culture solution is aspirated, the OD value is measured at 530nm wavelength by using an enzyme-labeling instrument after 3 minutes of low-speed shaking, the survival rate of the cells is calculated, and the result is shown in figure 4.
TABLE 2 culture solution preparation recipe
The experimental result shows that the cell survival rate of the andrographolide-gamma-cyclodextrin-surfactant ternary system pharmaceutical composition is equivalent to that of the andrographolide-gamma-cyclodextrin composition and the andrographolide bulk drug, the increase of the surfactant does not increase the cytotoxicity of the pharmaceutical composition, and the concentrations of the selected drugs and the auxiliary materials are within a safe range.
EXAMPLE 5 MDCK-MDR1 cellular uptake assay of Andrographolide-gamma-cyclodextrin-surfactant ternary System
The operation method comprises the step of inoculating the MDCK-MDR1 cells into a 6-well plate in a suspension manner, wherein the inoculation density is 5 × 105Per well. Placing the cells inAt 5% CO2Culturing overnight in an incubator at 37 ℃, removing old culture solution by suction, adding fresh culture solution with the prescribed concentration of 2m L (see table 3), putting the cells after adding the drugs back into the incubator for culturing for 90 minutes, removing old culture solution by suction, immediately washing the cells with cold PBS three times, removing andrographolide on the surfaces of the cells, adding 200 mu L Triton X-100 to lyse the cells for 30 minutes, collecting the cells, performing ultrasonic treatment for 10 minutes, centrifuging the cells, taking supernatant, and analyzing the content of andrographolide in the cells by using high performance liquid chromatography, wherein the results are shown in figure 5.
TABLE 3 recipe for culture solution preparation
The experimental result shows that the cell uptake concentration of the andrographolide-gamma-cyclodextrin-surfactant ternary system pharmaceutical composition is obviously higher than that of the commercially available dropping pill, the andrographolide-gamma-cyclodextrin composition and the andrographolide bulk drug, wherein the cell uptake concentration of the andrographolide-gamma-cyclodextrin-vitamin E-polyethylene glycol succinate ternary system pharmaceutical composition is the highest and is about 1.6 times that of the commercially available dropping pill.
Example 6 transmembrane transport assay of Andrographolide-gamma-cyclodextrin-vitamin E-polyethylene glycol succinate ternary System in MDCK-MDR1 cells
The operation method comprises the steps of inoculating MDCK-MDR1 cells in a Transwell chamber in a suspension manner, wherein the inoculation density is 5 × 105Per well. Place the cells in 5% CO2After 7 days of incubation at 37 ℃ in an incubator, the cells were washed twice with HBSS buffer solution at 37 ℃ and pH7.4, and allowed to equilibrate for 30 minutes in the incubator, after the old buffer was aspirated, 1.5m L HBSS buffer solution (see Table 4) was added to the inside of the Transwell cell and 2.6m L HBSS buffer solution was added to the bottom side of the Transwell cell for the A L-BP end, 2.6m L HBSS buffer solution (see Table 4) was added to the bottom side of the Transwell cell and 1.5m L HBSS buffer solution was added to the inside of the Transwell cell for the BP-A L end, and the cells were returned to the incubatorAnd at 15, 30, 45, 60, 90 and 120 minutes, 1m L solution was taken from the non-drug-added end and the same volume of HBSS buffer was added back and returned to the incubator, and the solution was analyzed for the rate of cell absorption and efflux by HPLC, as shown in FIG. 6.
TABLE 4 prescription of buffer solution
The experimental result shows that the cellular absorption rate of the andrographolide medicinal composition is equivalent to that of andrographolide dropping pills and andrographolide bulk drugs; however, the cell efflux rate of the andrographolide medicinal composition is obviously less than that of andrographolide dropping pills and andrographolide bulk drugs.
Example 7 preparation of a ternary pharmaceutical composition of andrographolide-gamma-cyclodextrin-vitamin E-polyethylene glycol succinate
(1) Prescription of andrographolide pharmaceutical composition
Andrographolide 2.00g
14.81g of gamma-cyclodextrin
Vitamin E-polyethylene glycol succinate 0.17g
(2) The preparation method comprises the steps of weighing the vitamin E-polyethylene glycol succinate with the prescription amount, dissolving the vitamin E-polyethylene glycol succinate in a small amount of water (about 20m L), weighing the gamma-cyclodextrin with the prescription amount, placing the gamma-cyclodextrin into a mortar, adding the vitamin E-polyethylene glycol succinate aqueous solution, stirring to dissolve the cyclodextrin, adding the andrographolide with the prescription amount into the mortar, fully grinding for 2 hours to be pasty, and drying in vacuum to obtain the final product.
EXAMPLE 8 in vitro characterization and in vivo bioavailability assay of Andrographolide-gamma-cyclodextrin-vitamin E-polyethylene glycol succinate ternary pharmaceutical composition
Experiment 1: solubility test of pharmaceutical composition containing andrographolide
Accurately weighing andrographolide 25mg, grinding to obtain andrographolide-gamma-cyclodextrin composition 210mg and andrographolide-containing pharmaceutical composition 212.1mg (both equivalent to andrographolide 25mg) prepared in example 7, dissolving in 5m L deionized water, shaking in a constant temperature shaking box at 37 deg.C for 48 hr, after complete dissolution, centrifuging to obtain supernatant, filtering with 0.45 μm microporous membrane, discarding the primary filtrate, detecting the sample solution with high performance liquid chromatography at wavelength of 225nm, and calculating andrographolide solubility by external standard method, with the results shown in FIG. 7.
Experiment 2: solubility experiment of pharmaceutical composition containing andrographolide and in-vitro dissolution experiment of andrographolide-gamma-cyclodextrin
According to the second method for measuring the release rate under the item 0931 in the fourth part of the Chinese pharmacopoeia 2015 edition, four different mediums (0.1 mol/L hydrochloric acid solution, phosphate buffer solution with pH6.8, water and 1% sodium dodecyl sulfate solution) are selected as release mediums, the volume of the release mediums is 1000m L, the temperature is controlled at (37 +/-0.5) DEG C, and the rotating speed is 75 r.min-1Taking 5m L of solution at 5min, 10 min, 15 min, 20 min, 30 min, 45 min and 60min, filtering with a 0.45 μm microporous membrane, discarding the primary filtrate, taking the secondary filtrate for later use, immediately supplementing 5m L of blank medium solution, detecting at 225nm by high performance liquid chromatography, and calculating the dissolution rate of andrographolide at different time points by external standard method, as shown in FIG. 8 (A: 0.1 mol/L hydrochloric acid, B: pH6.8 phosphate buffer, C: water, D: 1% sodium dodecyl sulfate solution).
Experiment 3: differential scanning calorimetry detection experiment of pharmaceutical composition containing andrographolide
Andrographolide, gamma-cyclodextrin, tocopheryl polyethylene glycol succinate, physical mixture of the formulation and andrographolide formulation (i.e. the pharmaceutical composition containing andrographolide prepared in example 7) were prepared in parallel, and the sample was analyzed using a differential scanning calorimeter model DSC-60, and the sample (about 3mg) was precisely weighed, and the DSC analysis conditions were set as follows: the scanning range is 30-250 ℃, and the heating rate is 10 ℃ min-1The scanning environment is a nitrogen environment, and the result is shown in FIG. 9。
Experiment 4: fourier transform infrared spectrum detection experiment for pharmaceutical composition containing andrographolide
Andrographolide, gamma-cyclodextrin, vitamin E-polyethylene glycol succinate, a physical mixture of the formulations and andrographolide formulation (i.e. the pharmaceutical composition containing andrographolide prepared in example 7) were prepared in parallel, the samples were analyzed using a fourier infrared spectrometer, and the sample powder and KBr were co-ground and pressed into thin sheets for infrared scanning analysis. The scanning range is 400-4000cm-1Scanning speed of 2cm-1The results are shown in FIG. 10.
Experiment 5: in vivo pharmacokinetics experiment of pharmaceutical composition containing andrographolide for rats
Andrographolide, commercially available andrographolide drops and andrographolide formulations (i.e. the pharmaceutical composition containing andrographolide prepared in example 7) were prepared in parallel for comparative experiments, 18 healthy SD male rats, weighing 250 ± 20 mg, were provided by the animal center of the health institute of australia university, fasted for 12 hours a day before the experiment, water was freely drunk, the animals were randomly divided into three groups of 6 animals each, andrographolide bulk drug, andrographolide drop pill and andrographolide formulation were administered separately, single dose administration was performed, dose was 40mg/kg BW. three groups of rats were each drenched with andrographolide bulk drug, andrographolide drop pill and andrographolide formulation, 0, 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, 24 hours after administration, jugular vein blood was taken at 300 μ L, the plasma was transferred to heparin coated, centrifuged at 5000rpm for 5min, separated, placed at-80 ℃ and stored, ready to use, time points of plasma concentration was determined by hplc, blood concentration calculation, and the results are shown in the centrifuge tube 11.
Table 5 shows the pharmacokinetic parameters of the andrographolide-containing pharmaceutical composition of the present invention in rats, where API is andrographolide bulk drug, DP is andrographolide dropping pill, and AG-CD is high-solubility andrographolide formula, i.e. the andrographolide-containing pharmaceutical composition prepared in example 7 of the present invention.
TABLE 5 measurement results of pharmacokinetic parameters
The experiments are combined, the andrographolide-containing pharmaceutical composition has high solubility, the in vitro dissolution rate of the andrographolide-containing pharmaceutical composition is obviously superior to that of the commercially available andrographolide dropping pills, and DSC experiments show that the andrographolide-containing pharmaceutical composition is not simply and physically mixed with materials in a formula, but forms a new composition. The in vivo pharmacokinetic experiment of the rats shows that the pharmaceutical composition containing andrographolide has short peak reaching time of blood concentration and quick absorption; the area under the blood concentration-time curve (AUC) is about 1.6 times of that of the andrographolide dropping pills sold in the market, and the bioavailability is obviously improved.
EXAMPLE 9 preparation of tablets of pharmaceutical composition of Andrographolide
In this example, a wet granulation tabletting method is adopted, and the specific operations are as follows: according to the preparation method of the andrographolide pharmaceutical composition in embodiment 8, andrographolide, gamma-cyclodextrin and vitamin E-polyethylene glycol succinate are prepared into the andrographolide pharmaceutical composition, the andrographolide pharmaceutical composition is uniformly mixed with microcrystalline cellulose and hypromellose, 50% ethanol is used as a wetting agent to be added into mixed powder to prepare a soft material, the soft material is granulated through a 40-mesh nylon sieve, the soft material is dried at 50-60 ℃, the dried granules are screened through a 40-mesh sieve to be granulated, the granulated granules are uniformly mixed with magnesium stearate, and a single-punch tablet press is used for tabletting. The specification of the tablet is phi 10mm, and the tabletting pressure is 4-5 kN. The amounts of the drugs and adjuvants are shown in table 6.
TABLE 6 Andrographolide tablet formulation
| Andrographolide | 0.5g |
| Gamma-cyclodextrin | 3.7g |
| Vitamin E-polyethylene glycol succinate | 0.043g |
| Microcrystalline cellulose | 4.25g |
| Hydroxypropyl methylcellulose | 0.85g |
| Magnesium stearate | Appropriate amount (1%) |
| Pressing | 20 pieces |
Example 10 preparation of Andrographolide pharmaceutical composition capsules
According to the preparation method of the andrographolide pharmaceutical composition in example 8, andrographolide, gamma-cyclodextrin and vitamin E-polyethylene glycol succinate are prepared into an andrographolide pharmaceutical composition, and the pharmaceutical powder is sieved by a 40-mesh sieve and then directly filled into a No. 2 capsule. The amounts of the drugs and adjuvants are shown in table 7.
TABLE 7 Andrographolide Capsule prescription
| Andrographolide | 0.5g |
| Gamma-cyclodextrin | 3.7g |
| Vitamin E-polyethylene glycol succinate | 0.043g |
The above-mentioned embodiments, objects, technical solutions and advantageous results of the present invention are further described in detail, it should be understood that the above-mentioned embodiments are only examples of the present invention and are not intended to limit the present invention, and any modifications, equivalents, improvements and the like made within the spirit and principle of the present invention should be included in the protection scope of the present invention.
Claims (10)
1. A pharmaceutical composition containing andrographolide, wherein the pharmaceutical composition comprises: a) andrographolide, b) cyclodextrin and c) surfactant, wherein the molar ratio of andrographolide to cyclodextrin is 1: 2-1: 5, and the surfactant accounts for 0.1% -5% of the pharmaceutical composition by mass.
2. The pharmaceutical composition of claim 1, wherein the molar ratio of the andrographolide to the cyclodextrin is 1: 2-1: 3, and the surfactant accounts for 0.1% -1% of the pharmaceutical composition by mass.
3. The pharmaceutical composition of claim 2, wherein the cyclodextrin is selected from one or more of α -cyclodextrin, β -cyclodextrin, γ -cyclodextrin, hydroxypropyl- β -cyclodextrin, methyl- β -cyclodextrin or sulfobutyl- β -cyclodextrin.
4. The pharmaceutical composition of claim 1, wherein the surfactant is selected from one or more of sodium lauryl sulfate, sodium cetyl sulfate, tween 60, tween 80, benzyl S10, benzyl S20, vitamin E-polyethylene glycol succinate, poloxamer P188, poloxamer P407, and polyoxyethylene castor oil E L.
5. The pharmaceutical composition of claim 3, wherein the cyclodextrin is γ -cyclodextrin.
6. The pharmaceutical composition of claim 4, wherein the surfactant is one or more selected from the group consisting of Tween 80, vitamin E-polyethylene glycol succinate, poloxamer P407 and polyoxyethylated castor oil E L.
7. The pharmaceutical composition of claim 6, wherein the surfactant is vitamin E-polyethylene glycol succinate.
8. The pharmaceutical composition of claim 2, wherein the molar ratio of andrographolide to cyclodextrin is 1: 2.
9. The pharmaceutical composition of claim 2, wherein the surfactant is present in an amount of 1% by weight of the pharmaceutical composition.
10. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition is in the form of any one of tablets, capsules, pills, granules, pellets, suspensions, solutions, emulsions, syrups or elixirs.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811652632.0A CN111388466A (en) | 2018-12-28 | 2018-12-28 | Pharmaceutical composition containing andrographolide and preparation thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811652632.0A CN111388466A (en) | 2018-12-28 | 2018-12-28 | Pharmaceutical composition containing andrographolide and preparation thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111388466A true CN111388466A (en) | 2020-07-10 |
Family
ID=71410709
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811652632.0A Pending CN111388466A (en) | 2018-12-28 | 2018-12-28 | Pharmaceutical composition containing andrographolide and preparation thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111388466A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114913927A (en) * | 2021-02-08 | 2022-08-16 | 欧阳德方 | Method for developing pharmaceutical composition and predicting and evaluating pharmaceutical composition |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102343096A (en) * | 2010-07-26 | 2012-02-08 | 香港城市大学 | Andrographolide cyclodextrin inclusion compound, preparation method and application thereof |
| CN106377500A (en) * | 2016-11-22 | 2017-02-08 | 南京中医药大学 | Andrographolide nano suspension and preparation method thereof |
-
2018
- 2018-12-28 CN CN201811652632.0A patent/CN111388466A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102343096A (en) * | 2010-07-26 | 2012-02-08 | 香港城市大学 | Andrographolide cyclodextrin inclusion compound, preparation method and application thereof |
| CN106377500A (en) * | 2016-11-22 | 2017-02-08 | 南京中医药大学 | Andrographolide nano suspension and preparation method thereof |
Non-Patent Citations (2)
| Title |
|---|
| HONGZHI QIAO等: "Fabrication and in vitro/in vivo evaluation of amorphous andrographolide nanosuspensions stabilized by D-α-tocopheryl polyethylene glycol 1000 succinate/sodium lauryl sulfate", 《INTERNATIONAL JOURNAL OF NANOMEDICINE》 * |
| PING DU等: "Nanonization of andrographolide by a wet milling method:the effects of vitamin E TPGS and oral bioavailability enhancement", 《RSC ADVANCES》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114913927A (en) * | 2021-02-08 | 2022-08-16 | 欧阳德方 | Method for developing pharmaceutical composition and predicting and evaluating pharmaceutical composition |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2342926C2 (en) | Method of obtaining of low crystallinity or amorphous oltipraz | |
| JP4334869B2 (en) | Compositions with improved solubility or oral absorption | |
| RU2461382C2 (en) | Revaprazan-containing solid dispersion and method for preparing it | |
| TW201311236A (en) | Celecoxib solid dispersion and its preparation method | |
| CN102342907A (en) | Dronedarone solid dispersoid and preparation method thereof | |
| CN102600132B (en) | Oral preparation containing amisulpride | |
| CN104644543A (en) | Dabigatran-containing solid dispersion and preparation method as well as application thereof | |
| CN111514142B (en) | Pharmaceutical composition containing nitroxoline prodrug and preparation method and application thereof | |
| CN110711176A (en) | Cilnidipine nanosuspension and preparation method thereof | |
| CN102406622A (en) | Tolvaptan solid preparation | |
| CN111388466A (en) | Pharmaceutical composition containing andrographolide and preparation thereof | |
| CN104069068A (en) | S-propargyl-cysteine solid dispersion, as well as preparation method and application thereof | |
| CN104884050A (en) | Pharmaceutical composition for treatment of hiv infections | |
| CN102793673A (en) | Solid dispersion body of berberine-phospholipid complex and preparation method thereof | |
| CN112569190B (en) | Oral administration preparation of pulsatilla chinensis saponin B4 and preparation method thereof | |
| CN107865826B (en) | Solid dispersion of E-configuration benzamide compound | |
| CN108186590A (en) | Huperzine slow-release orally disintegrating tablets and preparation method thereof | |
| KR100539706B1 (en) | Solid dispersion comprising tacrolimus and enteric-coated macromolecule | |
| KR101088845B1 (en) | Solid dispersion comprising an extract of Scutellariae radix, the oral formulation comprising the same and the preparation method thereof | |
| CN104288141A (en) | Simvastati-containing solid medicinal composition and its preparation method | |
| Saritha et al. | Preparation and evaluation of solid dispersions of Ofloxacin | |
| CN104800191A (en) | Lyophilized zolmitriptan nanometer powder and preparation method thereof | |
| KR101631056B1 (en) | Solid dispersion formulation for improving the dissolution of lignan from schisandra chinensis extract | |
| KR20130062691A (en) | Rapid solid dispersion oral compsition for using wheat bran | |
| US20220401425A1 (en) | Chidamide pharmaceutical composition, preparation method therefor and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB02 | Change of applicant information |
Address after: The University of Macao Taipa China Applicant after: University OF MACAU Address before: Taipa University Avenue Applicant before: University OF MACAU |
|
| CB02 | Change of applicant information |